BioLineRx concludes enrolment in intratumoural cancer vaccine trial
BioLineRx has completed enrolment in Phase I/IIa trial of its intratumoural cancer vaccine, AGI-134, to treat solid tumour patients.
Source: clinicaltrialsarena.com
Stay updated with breaking news from Sample Services. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BioLineRx has completed enrolment in Phase I/IIa trial of its intratumoural cancer vaccine, AGI-134, to treat solid tumour patients.
Sciwind Biosciences has commenced participant dosing in Phase IIb trial of GLP-1 drug candidate, XW003, in individuals with obesity.